JP2004538332A5 - - Google Patents

Download PDF

Info

Publication number
JP2004538332A5
JP2004538332A5 JP2003520770A JP2003520770A JP2004538332A5 JP 2004538332 A5 JP2004538332 A5 JP 2004538332A5 JP 2003520770 A JP2003520770 A JP 2003520770A JP 2003520770 A JP2003520770 A JP 2003520770A JP 2004538332 A5 JP2004538332 A5 JP 2004538332A5
Authority
JP
Japan
Prior art keywords
motomeko
conjugate
polyamino acid
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003520770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004538332A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2002/000547 external-priority patent/WO2003015812A2/en
Publication of JP2004538332A publication Critical patent/JP2004538332A/ja
Publication of JP2004538332A5 publication Critical patent/JP2004538332A5/ja
Pending legal-status Critical Current

Links

JP2003520770A 2001-08-20 2002-08-20 β−アミロイドアナログ−Ｔ細胞エピトープワクチン Pending JP2004538332A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200101231 2001-08-20
US33754301P 2001-10-22 2001-10-22
US37302702P 2002-04-16 2002-04-16
DKPA200200558 2002-04-16
PCT/DK2002/000547 WO2003015812A2 (en) 2001-08-20 2002-08-20 Beta-amyloid-analogue-t-cell epitop vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009141187A Division JP5114455B2 (ja) 2001-08-20 2009-06-12 β−アミロイドアナログ−Ｔ細胞エピトープワクチン

Publications (2)

Publication Number Publication Date
JP2004538332A JP2004538332A (ja) 2004-12-24
JP2004538332A5 true JP2004538332A5 (enExample) 2006-01-05

Family

ID=32870659

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003520770A Pending JP2004538332A (ja) 2001-08-20 2002-08-20 β−アミロイドアナログ−Ｔ細胞エピトープワクチン
JP2009141187A Expired - Fee Related JP5114455B2 (ja) 2001-08-20 2009-06-12 β−アミロイドアナログ−Ｔ細胞エピトープワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009141187A Expired - Fee Related JP5114455B2 (ja) 2001-08-20 2009-06-12 β−アミロイドアナログ−Ｔ細胞エピトープワクチン

Country Status (29)

Country Link
US (3) US20030157117A1 (enExample)
EP (3) EP1685847A1 (enExample)
JP (2) JP2004538332A (enExample)
KR (3) KR101057488B1 (enExample)
CN (1) CN101675992B (enExample)
AR (1) AR036270A1 (enExample)
AT (1) ATE334698T1 (enExample)
AU (3) AU2002325199B2 (enExample)
BR (1) BR0212047A (enExample)
CA (1) CA2457140C (enExample)
CO (1) CO5560581A2 (enExample)
CY (1) CY1105737T1 (enExample)
DE (1) DE60213615T3 (enExample)
DK (1) DK1420815T3 (enExample)
EA (2) EA011610B1 (enExample)
ES (1) ES2269749T5 (enExample)
HR (2) HRP20040218A2 (enExample)
HU (1) HUP0400669A3 (enExample)
IL (2) IL159964A0 (enExample)
IS (1) IS7133A (enExample)
ME (1) MEP43208A (enExample)
MX (1) MXPA04001467A (enExample)
MY (1) MY144532A (enExample)
NZ (2) NZ547224A (enExample)
PL (1) PL215125B1 (enExample)
PT (1) PT1420815E (enExample)
RS (1) RS51699B (enExample)
SI (1) SI1420815T1 (enExample)
WO (1) WO2003015812A2 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
MXPA02007796A (es) * 2000-02-21 2003-12-08 Pharmexa As Metodo novedoso para la disminucion de cuerpos amiloides.
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US8506959B2 (en) * 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8697082B2 (en) * 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) * 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) * 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
KR100546066B1 (ko) * 2003-03-21 2006-01-26 한국생명공학연구원 베타아밀로이드 유전자의 다중 연결체를 발현하는 형질전환 식물 세포 및 이로부터 배양된 식물
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7807171B2 (en) 2003-07-25 2010-10-05 Ac Immune Sa Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers
WO2005042575A2 (en) * 2003-10-30 2005-05-12 Pharmexa A/S Method for down-regulation of vegf
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP2007522119A (ja) * 2004-01-28 2007-08-09 キュリックス エーピーエス アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート
KR100639397B1 (ko) * 2004-03-18 2006-10-26 (주)에스제이바이오메드 항비만용 면역원성 하이브리드 폴리펩타이드 및 이를포함하는 항비만 백신 조성물
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
BRPI0610093A2 (pt) * 2005-05-05 2008-12-09 Merck & Co Inc composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
CA2638775A1 (en) * 2006-02-22 2007-08-30 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide vaccine for inducing production of anti-amyloid-.beta.-peptide antibody
WO2008070284A2 (en) 2006-10-16 2008-06-12 Johnnie B. Byrd, Sr. Alzheimer's Center And Research Institute Amyloid beta peptides and methods of uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
DK3067066T3 (da) * 2007-02-23 2019-05-20 Prothena Biosciences Ltd Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
WO2008106657A2 (en) * 2007-03-01 2008-09-04 Intezyne Technologies, Inc. Encapsulated amyloid-beta peptides
WO2008124646A2 (en) * 2007-04-06 2008-10-16 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Use of amyloid proteins as vaccine scaffolds
TR201802286T4 (tr) 2007-04-20 2018-03-21 The Chemo Sero Therapeutic Res Institute Peptidle bağışıklık yanıtının arttırılması için yöntem.
WO2010005858A1 (en) * 2008-07-08 2010-01-14 Merck & Co., Inc. Vaccine for the treatment of alzheimer's disease
CN102245629B (zh) * 2008-10-16 2014-06-25 一般财团法人化学及血清疗法研究所 修饰的淀粉状蛋白β肽
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
US9289488B2 (en) 2010-08-12 2016-03-22 Ac Immune Sa Vaccine engineering
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
AR083561A1 (es) 2010-10-26 2013-03-06 Ac Immune Sa Preparacion de una construccion antigenica
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
AU2013305848B2 (en) * 2012-08-21 2020-10-15 Institute For Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, Tau, and alpha-synuclein
WO2015017280A1 (en) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
US20160220649A1 (en) * 2013-09-13 2016-08-04 Fundación Pública Andaluza Progreso Y Salud Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases
EP3116893B1 (en) * 2014-03-11 2019-08-28 Jacques Fantini A chimeric peptide that interacts with cell membrane gangliosides
EP3253419A1 (en) * 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
CN104880441B (zh) * 2015-05-14 2017-12-22 上海皓拓生物技术有限公司 β‑分泌酶特异性抑制剂的筛选方法及其筛选系统
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
HUE050403T2 (hu) 2016-10-28 2020-12-28 H Lundbeck As Imidazopirazinonokkal végzett kombinációs kezelések pszichiátriai és/vagy kognitív betegségek kezelésére
BR112018013084A2 (pt) 2016-10-28 2018-12-11 H Lundbeck As tratamentos de combinação compreendendo a administração de imidazopirazinonas
WO2018132768A1 (en) * 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
CN108187038B (zh) * 2017-05-25 2020-05-01 成都安特金生物技术有限公司 一种狂犬病结合疫苗
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
CN111465410B (zh) 2017-12-14 2022-10-25 H.隆德贝克有限公司 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗
JP7194738B2 (ja) 2017-12-20 2022-12-22 ハー・ルンドベック・アクチエゼルスカベット ＰＤＥ１阻害剤としてのピラゾロ［３，４－ｂ］ピリジン及びイミダゾ［１，５－ｂ］ピリダジン
US10828351B2 (en) * 2018-04-10 2020-11-10 Ac Immune Sa Anti-abeta therapeutic vaccines
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗
US12151000B2 (en) * 2019-04-12 2024-11-26 The Johns Hopkins University Tolerogenic artificial antigen-presenting cells
GB202008250D0 (en) * 2020-06-02 2020-07-15 Emergex Vaccines Holding Ltd Diagnosis, prevention and treatment of coronavirus infection
AU2022212600A1 (en) * 2021-01-29 2023-08-17 Bayer Animal Health Gmbh Vaccine composition for breaking self-tolerance
CN115925987A (zh) * 2022-02-28 2023-04-07 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用
CN117700525B (zh) * 2024-02-05 2024-06-18 上海良润生物医药科技有限公司 一种多肽改造体及其应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
JPS5938877A (ja) 1982-08-30 1984-03-02 Musashi Eng Kk 紙葉判別方法
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4608251A (en) 1984-11-09 1986-08-26 Pitman-Moore, Inc. LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US5223482A (en) 1986-11-17 1993-06-29 Scios Nova Inc. Recombinant Alzheimer's protease inhibitory amyloid protein and method of use
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5192688A (en) 1988-08-15 1993-03-09 Switzer Iii Robert C Histological analysis method
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
US5200339A (en) 1990-08-17 1993-04-06 Abraham Carmela R Proteases causing abnormal degradation of amyloid β-protein precursor
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5780036A (en) 1991-08-26 1998-07-14 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepattis B virus
KR950700081A (ko) 1992-02-11 1995-01-16 W 로우 죤 이중 캐리어 면역원성 구성물
CA2117884A1 (en) 1992-03-27 1993-10-14 Anna Aldovini Non-infectious hiv particles and uses therefor
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
AU4377793A (en) 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
DK100592D0 (da) 1992-08-10 1992-08-10 Mouritsen & Elsner Aps Metode til kemisk kobling paa faste faser
US5958883A (en) * 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
AU707083B2 (en) 1993-08-26 1999-07-01 Bavarian Nordic Inc. Inducing antibody response against self-proteins with the aid of foreign T-cell epitopes
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
EP0735893B1 (en) 1993-09-14 2008-11-26 Pharmexa Inc. Pan dr-binding peptides for enhancement of the immune response
AUPM411994A0 (en) 1994-02-25 1994-03-24 Deakin Research Limited Epitopes
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
US5573916A (en) 1994-05-19 1996-11-12 Coretech, Inc. Immunogenic constructs comprising b-cell and t-cell epitopes on common carrier
IL115743A0 (en) 1994-10-28 1996-01-19 American Nat Red Cross A mammal with cells containing a transgene and its production
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
ATE339436T1 (de) 1995-06-07 2006-10-15 Sanofi Pasteur Inc Expression von lipoproteinen
US5874469A (en) 1996-01-05 1999-02-23 Alcon Laboratories, Inc. Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs
US5985581A (en) 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
EP1837017A3 (en) 1997-01-22 2009-12-23 Eisai Inc. Microparticles for delivery of nucleic acid
AU1388899A (en) 1997-11-11 1999-05-31 Board Of Regents Of The University Of Oklahoma, The An alzheimer-related, endothelium-derived toxic factor and methods for its use
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6913745B1 (en) * 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
KR20010072025A (ko) 1998-07-21 2001-07-31 추후제출 활성화 폴리히드록시폴리머에 의한 고체 표면 코팅
IL141588A0 (en) 1998-09-15 2002-03-10 M & E Biotech As Method for down-regulating osteoprotegerin ligand activity
DE69918146T2 (de) 1998-10-05 2005-07-07 Pharmexa A/S Verfahren zur therapeutischen impfung
US6403537B1 (en) † 1998-11-06 2002-06-11 Baker Hughes Incorporated Drilling fluid systems with improved fluid loss properties
AU2495300A (en) 1999-01-07 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Lentivirus vector system
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US6787637B1 (en) * 1999-05-28 2004-09-07 Neuralab Limited N-Terminal amyloid-β antibodies
AR024558A1 (es) 1999-06-01 2002-10-16 Neuralab Ltd Composiciones del peptido a-beta y procesos para producir las mismas
AU784312B2 (en) 1999-11-29 2006-03-09 Bellus Health (International) Limited Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
JP4804690B2 (ja) * 1999-12-08 2011-11-02 インテレクト・ニューロサイエンシズ・インコーポレーテッド 免疫原としてのキメラペプチド、それに対する抗体、およびキメラペプチドまたは抗体を用いた免疫法
MXPA02007796A (es) 2000-02-21 2003-12-08 Pharmexa As Metodo novedoso para la disminucion de cuerpos amiloides.
JP5025871B2 (ja) * 2000-02-21 2012-09-12 エイチ．リュンドベック エイ／エス アミロイドの新規なダウン−レギュレート方法
GB0004530D0 (en) 2000-02-25 2000-04-19 Univ Nottingham Adjuvants
AU7487301A (en) * 2000-05-22 2001-12-03 Univ New York Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid beta for induction of an immune response to amyloid beta and amyloid deposits
HUP0600589A2 (en) 2000-11-10 2006-11-28 Wyeth Corp Adjuvant combination formulations
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
JP2002273199A (ja) * 2001-03-15 2002-09-24 Idemitsu Petrochem Co Ltd ガス状流体の抜き出し方法
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030185845A1 (en) 2001-11-16 2003-10-02 Steen Klysner Novel immunogenic mimetics of multimer proteins
AU2003203140A1 (en) 2002-01-17 2003-07-30 Pharmexa A/S Immunogenic carcinoembryonic antigen (cea)
AU2003208314A1 (en) 2002-03-11 2003-09-22 Pharmexa A/S Novel application of vaccination against tnf-alpha
US20040091945A1 (en) 2002-07-17 2004-05-13 Cheryl Fitzer-Attas Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease

Similar Documents

Publication Publication Date Title
JP2004538332A5 (enExample)
Chattergoon et al. Genetic immunization: a new era in vaccines and immune therapeutics
CA2457140A1 (en) Beta-amyloid-analogue - t-cell epitope vaccine
US8470560B2 (en) CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
CN103002909B (zh) 包含含有至少一个cxxc基序的多肽和异源抗原的药物组合物及其用途
CN101969990B (zh) 增强针对艾美球虫属的免疫反应的组合物和方法
CN102037135A (zh) 增强对有鞭毛的细菌的免疫反应的组合物和方法
US6537552B1 (en) Vaccine adjuvant
US7645455B2 (en) Chimeric lyssavirus nucleic acids and polypeptides
WO2007125535A1 (en) Recombinant flagellin gene and uses thereof
US20080076175A1 (en) Somatic transgene immunization and related methods
AU731706B2 (en) Recombinant viral pseudo-particles and vaccinal and antitumoral applications thereof
Perrin et al. DNA-based immunization against Lyssaviruses
US11185583B2 (en) Multi-functional mucosal vaccine platform
AU782663B2 (en) Antigen delivery
JPH02223594A (ja) ヒトライノウイルスペプチド
CA2370278C (en) Chimeric lyssavirus nucleic acids and polypeptides
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
JP2009502880A (ja) 毒素に対する電気移動による遺伝子免疫法および前記方法によって得られる抗血清
EP1721982B1 (en) Chimeric lyssavirus nucleic acids and polypeptides
CN119894531A (zh) Tau肽免疫原构建体
CN121160677A (en) Preparation and application of particle antigen
Mažeikė Generation of anticancer vaccine based on virus-like particles
Bona Principles of Vaccine Development